Results 261 to 270 of about 116,257 (347)

The Burden of Antimicrobial‐Resistant Pseudomonas aeruginosa Isolates in Children With Cystic Fibrosis: Molecular Characterization and Genotyping Analysis

open access: yesMicrobiologyOpen, Volume 15, Issue 1, February 2026.
This study highlights the prevalence of multidrug‐ and carbapenem‐resistant Pseudomonas aeruginosa in pediatric cystic fibrosis patients, along with the presence of carbapenemase‐encoding genes and genetic profiles, suggesting clonal spread. These findings underscore the urgent need for surveillance and strategies to combat resistant strains and ...
Erfaneh Jafari   +5 more
wiley   +1 more source

Genomic, Evolutionary and Phenotypic Insights into <i>Pseudomonas</i> Phage Adele, a Novel <i>Pakpunavirus</i> with Potential for Phage Therapy. [PDF]

open access: yesViruses
Chaplin AV   +13 more
europepmc   +1 more source

Tumor Immunotherapy and Microbiome: From Bench‐to‐Bedside Applications

open access: yesMedComm, Volume 7, Issue 2, February 2026.
The microbiome is related to the efficacy of immunotherapy and can be utilized to predict the efficacy and adverse reactions of immunotherapy. Microbiome‐targeted intervention strategies can improve the efficacy of ICI, but necessitating more comprehensive exploration.
Anqi Lin   +12 more
wiley   +1 more source

[Phage therapy in Germany-Update 2025]. [PDF]

open access: yesBundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz
Willy C, Bröcker F.
europepmc   +1 more source

Tetravalent antibodies are more potent and efficacious erythropoiesis‐stimulating agents than erythropoietin in vivo

open access: yesProtein Science, Volume 35, Issue 2, February 2026.
Abstract Recent studies have shown that tetravalent antibodies are potent and efficacious agonists of the erythropoietin (EPO) receptor (EPOR) both in vitro and in vivo. To identify antibody‐based erythropoiesis‐stimulating agents (ESAs) with therapeutic potential, we evaluated various tetravalent antibody formats for EPOR agonism and key biophysical ...
Jarrett J. Adams   +20 more
wiley   +1 more source

Phage Therapy for Urinary Tract Infections: Progress and Challenges Ahead. [PDF]

open access: yesInt Urogynecol J
Morgan CJ   +7 more
europepmc   +1 more source

Advances in Therapeutic Antibody Discovery and Development Targeting G Protein‐Coupled Receptors

open access: yesPharmacology Research &Perspectives, Volume 14, Issue 1, February 2026.
ABSTRACT G protein‐coupled receptors (GPCRs) are integral to numerous biological processes and are associated with various diseases across all therapeutic areas. Consequently, GPCRs present substantial potential for antibody‐based therapies. This review offers an overview of the therapeutic GPCR‐antibody target landscape and examines the diversity ...
Catherine J. Hutchings   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy